Moreover, intravenous injection of recombinant ApoA1 was shown to efficiently reduce Aβ load in the AD mouse model [167], thus identifying manipulation of CSF apolipoproteins as a promising strategy for future therapeutic applications for brain-related diseases. This evidence concerns the gene APOA1 and Alzheimer disease.